%0 Journal Article %T 4-1BB-mediated cancer immunotherapy: ‘mission impossible’ for non-engineered IgGs? %A Alvarez-Vallina, Luis %J Precision Cancer Medicine %D 2019 %B 2019 %9 %! 4-1BB-mediated cancer immunotherapy: ‘mission impossible’ for non-engineered IgGs? %K %X Increasing tumor-specific immune responses with immunostimulatory monoclonal antibodies (mAbs) is a promising strategy in cancer therapy. Antagonistic mAbs blocking signaling through inhibitory receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) have been shown to induce sustained anti-tumor responses in many cancers across various histologies, and agonistic mAbs targeting activator receptors are undergoing clinical trials (1). %U https://pcm.amegroups.org/article/view/4665 %V 2 %P %@ 2617-2216